Genzyme to Market Elaprase in Japan (Japan)
This article was originally published in PharmAsia News
Genzyme Corp. has gotten approval from the Japanese government to begin distributing Elaprase in Japan. As part of a deal with Shire Human Genetic Therapies, Genzyme will market Elaprase in Asia. In addition to Japan, Genzyme expects to receive approval for the drug in Australia by the end of 2007, as well as Taiwan and South Korea in 2008. Elaprase is used to treat patients with Hunter syndrome, a rare genetic disorder that causes severe and eventually fatal damage to tissues and organs. Genzyme has been doing business in Japan for 20 years and currently has about 100 employees working in the country. Elaprase is the fifth enzyme replacement therapy the company has introduced there. (Click here for more
You may also be interested in...
US FDA looks to post-marketing studies to address elements of the NDA that were not central to its initial swift approval as the first COVID-19 therapy, including pediatric use and the interaction of hepatotoxicity and dose duration.
But advisory committee members caution against including pediatric population in COVID-19 vaccine trials, and one member expresses concern that Pfizer is testing those as young as 12 years of age. Agency is in discussions with product sponsors about enrollment of adolescents.
Public Company Edition: Four health care special purpose acquisition vehicles went public and two others announced mergers, but only one biopharma firm priced an IPO during the week of 19-23 October. Replimune’s $250m offering led recent FOPOs.